Abstract
Abstract
Background
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a neglected disease that affects ~7 million people worldwide. Development of new drugs to treat the infection remains a priority since those currently available have frequent side effects and limited efficacy at the chronic stage. Natural products provide a pool of diversity structures to lead the chemical synthesis of novel molecules for this purpose. Herein we analyzed the anti-T. cruzi activity of nine alkaloids derived from plants of the family Amaryllidaceae.
Methods
The activity of each alkaloid was assessed by means of an anti-T. cruzi phenotypic assay. We further evaluated the compounds that inhibited parasite growth on two distinct cytotoxicity assays to discard those that were toxic to host cells and assure parasite selectivity.
Results
We identified a single compound (hippeastrine) that was selectively active against the parasite yielding selectivity indexes of 12.7 and 35.2 against Vero and HepG2 cells, respectively. Moreover, it showed specific activity against the amastigote stage (IC50 = 3.31 μM).
Conclusions
Results reported here suggest that natural products are an interesting source of new compounds for the development of drugs against Chagas disease.
Funder
Agència de Gestió d’Ajuts Universitaris i de Recerca
Instituto de Salud Carlos III
CYTED Ciencia y Tecnología para el Desarrollo
Departament de Salut, Generalitat de Catalunya
Ministerio de Ciencia, Innovación y Universidades
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference47 articles.
1. WHO. Chagas disease (American trypanosomiasis). https://www.who.int/en/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis). Accessed 4 Mar 2020.
2. Pinazo MJ, Gascon J. Chagas disease: from Latin America to the world. Reports Parasitol. 2015;4:7–14.
3. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100.
4. Alonso-Padilla J, Gállego M, Schijman AG, Gascon J. Molecular diagnostics for Chagas disease: up to date and novel methodologies. Expert Rev Mol Diagn. 2017;17:699–710.
5. Crespillo-Andujar C, Venanzi-Rullo E, López-Vélez R, Monge-Maillo B, Norman F, López-Polín A, et al. Safety profile of benznidazole in the treatment of chronic Chagas disease: experience of a referral centre and systematic literature review with meta-analysis. Drug Saf. 2018;41:1035–48.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献